10 vial
Cagrilintide is a long-acting analogue of human amylin, a pancreatic serum co-secreted with insulin that regulates satiety, gastric emptying and post-prandial glucose excursions. It is studied both as a standalone investigational agent and in combination with GLP-1 receptor agonists for amplified weight-loss and glycaemic outcomes.
Checking availability…
Activates amylin receptors in the area postrema and other hindbrain nuclei to suppress appetite and reduce food intake. Also slows gastric emptying and modulates post-meal glucagon secretion, complementing the incretin effects of GLP-1-based therapies.
Common research protocols start at 0.3–0.6mg subcutaneously once daily, with gradual escalation based on tolerability. Cycles typically run 12–24 weeks. Subcutaneous administration in the abdomen, thigh or upper arm is standard.
Extended half-life of several days due to acylation, supporting daily or less frequent dosing depending on formulation.
Reconstitute a 10mg vial with 2–3mL bacteriostatic water for a 3.3–5mg/mL working concentration. Swirl gently - do not shake.
Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 28 days.
Please confirm your age to continue.
For research use only